Abstract
In the medical treatment of Peyronie’s disease (PD), various agents and their combinations continue to be used. However, there is no standardized treatment. The expectation from an effective treatment agent is that it leads to the regression of the fibrotic plaque and penile curvature and improves the patient’s sexual life. The present study aims to determine the effect of the combination of colchicine, pentoxifylline and tadalafil in the acute phase of PD.
Retrospective data of patients who presented with acute phase PD between 2004-2024 and received combined medical treatment (tadalafil 5 mg once a day + pentoxifylline 400 mg twice a day + colchicine 0.5 mg twice a day) were analyzed.
Average age of the 160 participants was 53.7 ± 9.7 years. The median curvature degree was 35° (IQR: 30-45°). Prior to treatment, 59 (36.9%) patients had penile pain and 87 (54.4%) patients had concomitant ED. At the posttreatment evaluation, median curvature degree was 30° (IQR: 15-45°). Out of the curvatures at the pretreatment period, 7 (4.4%) disappeared, 23 (14.4%) regressed and 72 (45%) remained stable. 34 (57.6%) of 59 patients with penile pain experienced improvement in their symptom. Risk factors for curvature progression after combined medical treatment were evaluated with logistic regression analysis. Only smoking habit (OR = 4.851; 95% CI = 2.164–9.695; p < 0.001) was stated as a risk factor for progression.
The combination of oral pentoxifylline, colchicine, and tadalafil may correct curvature in the acute phase of Peyronie’s disease and be an effective treatment option for pain relief. These results should be supported by large-scale studies with a high level of evidence.
none.
